
MAZE Stock Forecast & Price Target
MAZE Analyst Ratings
Bulls say
Maze Therapeutics Inc. is advancing its clinical-stage programs with encouraging Phase 1 results for the MZE782 compound, which demonstrated significant pharmacodynamic activity, including a 42-fold increase in urinary phenylalanine and a benign hemodynamic mechanism without tubular injury. The positive data not only strengthens confidence in target engagement and mechanistic plausibility but also suggests the potential for MZE782 to carve out significant market share as a safer hemodynamic modulator in treating chronic kidney disease (CKD). With its innovative Compass platform underpinning the development of small-molecule precision medicines, Maze Therapeutics is well-positioned to harness human genetics in addressing renal and cardiovascular diseases, supporting a favorable outlook on its stock performance.
Bears say
The financial outlook for Maze Therapeutics Inc appears negative due to several critical risks associated with its pipeline products, MZE782 and MZE829. Key concerns include the potential failure of these candidates in clinical studies, the inability to secure regulatory approval in major markets like the US and EU, and challenges in achieving projected peak commercial revenues due to factors such as market size and pricing pressures. Additionally, systemic safety liabilities may constrain even potentially transformative therapies in the renal space, heightening uncertainty around the company's prospects.
This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MAZE Analyst Forecast & Price Prediction
Start investing in MAZE
Order type
Buy in
Order amount
Est. shares
0 shares